Literature DB >> 25614331

Ror2 as a therapeutic target in cancer.

Zufan Debebe1, W Kimryn Rathmell2.   

Abstract

Ror2 is a signaling receptor for Wnt ligands that is known to play important roles in limb development, but having no essential roles known in adult tissues. Recent evidence has implicated Ror2 in mediating both canonical and non-canonical signaling pathways. Ror2 was initially found to be highly expressed in osteosarcoma and renal cell carcinomas, and has recently been found in an increasingly long list of cancers currently including melanoma, colon cancer, melanoma, squamous cell carcinoma of the head and neck, and breast cancer. In the majority of these cancer types, Ror2 expression is associated with more aggressive disease states, consistent with a role mediating Wnt signaling regardless of the canonical or noncanonical signal. Because of the pattern of tissue distribution, the association with high-risk diseases, and the cell surface localization of this receptor, Ror2 has been identified as a potential high value target for therapeutic development. However, the recent discovery that Ror2 may function through non-kinase activities challenges this strategy and opens up opportunities to target this important molecule through alternative means.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Pseudokinase; Receptor tyrosine kinase; Ror2; Wnt signaling

Mesh:

Substances:

Year:  2015        PMID: 25614331      PMCID: PMC9236825          DOI: 10.1016/j.pharmthera.2015.01.010

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   13.400


  80 in total

1.  Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2.

Authors:  Hiroyuki Yamamoto; Sa Kan Yoo; Michiru Nishita; Akira Kikuchi; Yasuhiro Minami
Journal:  Genes Cells       Date:  2007-11       Impact factor: 1.891

2.  Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity.

Authors:  Masaki Kobayashi; Yasuyuki Shibuya; Junichiro Takeuchi; Maho Murata; Hiroaki Suzuki; Satoshi Yokoo; Masahiro Umeda; Yasuhiro Minami; Takahide Komori
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03

3.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

Review 4.  The Ror receptor tyrosine kinase family.

Authors:  W C Forrester
Journal:  Cell Mol Life Sci       Date:  2002-01       Impact factor: 9.261

Review 5.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

6.  WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.

Authors:  Jose Roman-Gomez; Antonio Jimenez-Velasco; Lucia Cordeu; Amaia Vilas-Zornoza; Edurne San Jose-Eneriz; Leire Garate; Juan A Castillejo; Vanesa Martin; Felipe Prosper; Anabel Heiniger; Antonio Torres; Xabier Agirre
Journal:  Eur J Cancer       Date:  2007-12       Impact factor: 9.162

Review 7.  Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers.

Authors:  Ying Ying; Qian Tao
Journal:  Epigenetics       Date:  2009-07-25       Impact factor: 4.528

8.  The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src.

Authors:  Shiva Akbarzadeh; Lee M Wheldon; Steve M M Sweet; Sonia Talma; Faraz Khosravi Mardakheh; John K Heath
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

Review 9.  Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Int J Mol Sci       Date:  2014-08-08       Impact factor: 5.923

10.  The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.

Authors:  M P O'Connell; J L Fiori; M Xu; A D Carter; B P Frank; T C Camilli; A D French; S K Dissanayake; F E Indig; M Bernier; D D Taub; S M Hewitt; A T Weeraratna
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

View more
  40 in total

Review 1.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

2.  Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Authors:  Haiyong Peng; Thomas Nerreter; Jing Chang; Junpeng Qi; Xiuling Li; Pabalu Karunadharma; Gustavo J Martinez; Mohammad Fallahi; Jo Soden; Jim Freeth; Roger R Beerli; Ulf Grawunder; Michael Hudecek; Christoph Rader
Journal:  J Mol Biol       Date:  2017-08-14       Impact factor: 5.469

3.  The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

Authors:  M Frenquelli; N Caridi; E Antonini; F Storti; V Viganò; M Gaviraghi; M Occhionorelli; S Bianchessi; L Bongiovanni; A Spinelli; M Marcatti; D Belloni; E Ferrero; S Karki; P Brambilla; F Martinelli-Boneschi; S Colla; M Ponzoni; R A DePinho; G Tonon
Journal:  Leukemia       Date:  2019-05-31       Impact factor: 11.528

4.  Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.

Authors:  Jianjun Huang; Ying Shi; Hui Li; Dunyong Tan; Meisongzhu Yang; Xiang Wu
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

5.  Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.

Authors:  Jian Yu; Liguang Chen; Bing Cui; George F Widhopf; Zhouxin Shen; Rongrong Wu; Ling Zhang; Suping Zhang; Steven P Briggs; Thomas J Kipps
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

6.  Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.

Authors:  Joshua B Sheetz; Sebastian Mathea; Hanna Karvonen; Ketan Malhotra; Deep Chatterjee; Wilhelmiina Niininen; Robert Perttilä; Franziska Preuss; Krishna Suresh; Steven E Stayrook; Yuko Tsutsui; Ravi Radhakrishnan; Daniela Ungureanu; Stefan Knapp; Mark A Lemmon
Journal:  Mol Cell       Date:  2020-07-02       Impact factor: 17.970

7.  ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma.

Authors:  María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; María Belén Villanueva; Jérémie Nsengimana; Julia Newton-Bishop; Edith Illescas; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  J Cell Commun Signal       Date:  2022-06-20       Impact factor: 5.782

8.  MicroRNA-93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells.

Authors:  Yu He; Bo Yu
Journal:  Exp Ther Med       Date:  2017-03-08       Impact factor: 2.447

9.  Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications.

Authors:  Rebecca S Goydel; Justus Weber; Haiyong Peng; Junpeng Qi; Jo Soden; Jim Freeth; HaJeung Park; Christoph Rader
Journal:  J Biol Chem       Date:  2020-03-19       Impact factor: 5.157

Review 10.  WNT signalling in prostate cancer.

Authors:  Virginia Murillo-Garzón; Robert Kypta
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.